go back

Idecabtagene Vicleucel (Abecma), up to 460 Million Cells

Rhode Island rates for HCPCS C9081

Idecabtagene vicleucel, up to 460 million autologous anti-BCMA CAR-positive viable T cells, including leukapheresis and dose preparation procedures, per therapeutic dose

Rates data updated July 2026.

Facilitymedian $446,684 · 10th–90th $446,684$467,7350%50%90th$446,684Professionalmedian $457,088 · 10th–90th $457,088$457,0880%50%100%$457,088$500.0K

Distribution of negotiated rates across all payers (price axis is log-scale). Facility and professional rates are different services and are charted separately. Small sample; interpret with caution. Need provider-level prices? Contact us.

Insurance Carrier
BCBS
Setting
Facility
Modifier
Global
Typical Low
$446,683.59
Median
$446,683.59
Typical High
$467,735.14
BCBS
Setting
Professional
Modifier
Global
Typical Low
$457,088.19
Median
$457,088.19
Typical High
$457,088.19